Patients treated with Taltz demonstrated statistically significantly higher improvements than those treated with...
Taltz knocks down Tremfya in head-to-head trial in psoriasis patients
Patients treated with Taltz demonstrated statistically significantly higher improvements than those treated with Tremfya as measured by PASI 100 at Week 12.
Pfizer’s abrocitinib meets all endpoints in JADE MONO-1 study
Pfizer has reported positive results from the Phase III JADE MONO-1 clinical trial of its investigational Janus kinase 1 (JAK1) inhibitor, abrocitinib, in patients with moderate to severe atopic dermatitis.
Lilly’s Taltz meets primary goal in Phase IV plaque psoriasis trial
Eli Lilly has reported positive results from the head-to-head Phase IV IXORA-R clinical trial, where the company’s Taltz (ixekizumab) demonstrated superiority over Janssen’s Tremfya in plaque psoriasis.
Dermavant to recruit 30 patients in Phase IIa vitiligo trial
The Phase IIa trial will collect liquid from blisters to investigate whether cerdulatinib can reduce Chemokine, ligand 9 and CXCL10, which are upregulated during pigmentation abnormality in vitiligo patients.
Novartis’ Cosentyx demonstrates positive Phase III results in 16-week non-radiographic axial spondyloarthritis study
The ongoing Phase III study met its primary endpoint of patients achieving a 40% improvement in symptoms.
Akari enrols seven out of nine patients in bullous pemphigoid trial
Akari Therapeutics’ Phase II trial investigating Coversin (nomacopan) in mild-to-moderate bullous pemphigoid has so far enrolled seven out of its nine-patient target as of three to four weeks ago, a source with knowledge of the trial said. The trial was aimed to complete within six months but it is still enrolling in its eighth month, the source noted, adding it is hoped the final two patients would be recruited in the next couple of months.
Cassiopea’s Winlevi uptake in acne driven by new mechanism though interest to wane
While Cassiopea’s Winlevi (clascoterone) is likely to be FDA approved in moderate-to-severe acne, it is at risk of diminishing clinician/patient interest following initially optimistic early uptake, experts said. The market wane could happen if clinical trial data does not match real-world experience, even if early adoption would be driven by its novel antiandrogen mechanism, they said.
Medable and University of Pennsylvania partner in LITE study
US-based data-driven clinical trials provider Medable and the University of Pennsylvania School of Medicine have partnered to accelerate patient enrolment and increase participant retention in the Light Treatment Effectiveness (LITE) trial.